AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8437693
Drug: High-dose piracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose piracetam (8 g/d per os)
Trial: 24841974
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2 every 3 weeks)
Trial: 24841974
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg daily) in EGFR wild-type tumors
Trial: 24841974
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2 every 3 weeks) in EGFR wild-type tumors
Trial: 22290901
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol + remifentanil
Trial: 22290901
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia with sevoflurane
Trial: 19004511
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg, p.o., o.d. (n=13)
Trial: 18317188
Drug: Tantalum implant
RxNorm normalized name: tantalum
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tantalum implant
Trial: 8834341
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GP) 1.0 mg
Trial: 8834341
Drug: Nebulized metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized metaproterenol (MP) 15 mg
Trial: 8834341
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GP 1.0 mg and MP 15 mg (GP+MP)
Trial: 8834341
Drug: Control (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (either drug alone)
Trial: 3931899
Drug: Central parenteral
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central parenteral nutrition (CPN) for 4 weeks
Trial: 3931899
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN) for 4 weeks
Trial: 3931899
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) (weeks 1‐4)
Trial: 30799266
Drug: 30 5-mg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 5-mg oxycodone immediate-release (OxyIR) pills
Trial: 30799266
Drug: 90 5-mg
RxNorm normalized name: sulfacetamide sodium 90 MG/ML / sulfur 42.5 MG/ML [Clenia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 5-mg oxycodone immediate-release (OxyIR) pills
Trial: 26511996
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg TCZ+MTX
Trial: 26511996
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg TCZ+placebo
Trial: 26511996
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg TCZ+MTX
Trial: 24342385
Drug: PT +
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT + STIM (44.8 ± 14.6 mg/day) + placebo (1.88 mg/day ± 0.72)
Trial: 24342385
Drug: PT +
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT + STIM (46.1 ± 16.8 mg/day) + risperidone (1.65 mg/day ± 0.75)
Trial: 22267714
Drug: Vitamin D3,
RxNorm normalized name: Vitamin D3, 25 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3, 50,000 IU administered at 0, 4, and 8 weeks
Trial: 17106275
Drug: TMC120 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC120 vaginal microbicide gel (various concentrations)
Trial: 17106275
Drug: TMC120 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC120 vaginal microbicide gel
Trial: 10218041
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate ointment plus miconazole gel and 0.12% chlorhexidine mouthwashes
Trial: 10218041
Drug: 0.05% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% fluocinonide ointment plus miconazole gel and 0.12% chlorhexidine mouthwashes
Trial: 10218041
Drug: Placebo (hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (hydroxyethyl cellulose gel plus miconazole gel and 0.12% chlorhexidine mouthwashes)
Trial: 1688495
Drug: Modified LSA2L2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified LSA2L2 therapy
Trial: 31063156
Drug: 180mcg/kg/day palifermin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180mcg/kg/day palifermin for 3 days immediately prior to and after each cycle of alemtuzumab, with repeat doses at M1 and M3.
Trial: 23510984
Drug: Conatumumab 10
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conatumumab 10 mg/kg plus FOLFIRI (Arm A)
Trial: 23510984
Drug: Ganitumab 12
RxNorm normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganitumab 12 mg/kg plus FOLFIRI (Arm B)
Trial: 14508203
Drug: Thiazide-based antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide-based antihypertensive therapy
Trial: 3893512
Drug: Oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-acetylcysteine (200 mg thrice daily for 4 weeks)
Trial: 31153114
Drug: NaOCl treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOCl treatment for 20 minutes
Trial: 31153114
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment (200 °C)
Trial: 31153114
Drug: NaOCl treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOCl treatment followed by heat treatment (200 °C)
Trial: 31153114
Drug: Micro-Raman spectroscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-Raman spectroscopy after NaOCl treatment
Trial: 27783276
Drug: Mizoribine (MZR)
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years, with PSL starting at 40 mg/day and tapering, and MZR given once-a-day at 150 mg (group 1) or 3-times-a-day at 50 mg (group 2).
Trial: 27783276
Drug: Mizoribine (MZR)
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years.
Trial: 26392095
Drug: Granulocyte Colony-Stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF) + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Trial: 21816786
Drug: GW501516 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW501516 (2.5 mg/d)
Trial: 15292386
Drug: Epirubicin-paclitaxel (ET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin-paclitaxel (ET) chemotherapy
Trial: 15292386
Drug: Epirubicin-cyclophosphamide (EC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin-cyclophosphamide (EC) chemotherapy
Trial: 9146779
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin 6 mg/kg
Trial: 9146779
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin 1 mg/kg
Trial: 9146779
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (both dosages)
Trial: 7995207
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin
Trial: 8190679
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral ketorolac
Trial: 8190679
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of IM morphine
Trial: 8190679
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of IM morphine
Trial: 30091317
Drug: Early targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early targeted physical rehabilitation with standard sepsis treatment during hospitalization
Trial: 30091317
Drug: Standard sepsis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sepsis treatment
Trial: 24137215
Drug: Dexmedetomidine (0.2‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2‐0.5 μg/kg/h continuous intravenous infusion for 12 h)
Trial: 24137215
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline and isopropylphenol (2‐4 mg/kg/h intravenous infusion for postoperative sedation)
Trial: 21562445
Drug: Intravenous procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procaine (2 g/24 h) for 72 hours
Trial: 19485592
Drug: Family-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive-behavioral treatment (FCBT; N = 47) with exposure tasks
Trial: 16820589
Drug: Statin (pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (pravastatin 40 mg/d)
Trial: 16820589
Drug: AT1 blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1 blockade (irbesartan 150 mg/d)
Trial: 16820589
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of statin and AT1 blocker (same dosages)
Trial: 16820589
Drug: Statin, AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin, AT1 blocker, and their combination
Trial: 12759324
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate (10 mg daily)
Trial: 12759324
Drug: Alendronate alone
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate alone (10 mg daily)
Trial: 15240611
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy alone
Trial: 12759324
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with hormone replacement and alendronate
Trial: 12759324
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies (combination, alendronate, hormone replacement)
Trial: 9117313
Drug: Proctolog (trimebutine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proctolog (trimebutine suppository) applied immediately after haemorrhoidectomy
Trial: 9117313
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no suppository)
Trial: 2445114
Drug: no anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no anticoagulant treatment (control)
Trial: 16200817
Drug: Fexofenadine, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine, 180 mg once daily, with fluticasone propionate‐salmeterol, 250 microg twice daily
Trial: 16200817
Drug: Placebo, with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, with fluticasone propionate‐salmeterol, 250 microg twice daily
Trial: 16200817
Drug: Fexofenadine, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine, 180 mg once daily, with fluticasone propionate alone, 250 microg twice daily
Trial: 16200817
Drug: Placebo, with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, with fluticasone propionate alone, 250 microg twice daily
Trial: 12742470
Drug: Full-dose cyclosporine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose cyclosporine, fixed-dose sirolimus, and corticosteroids
Trial: 12742470
Drug: Reduced-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose cyclosporine and trough concentration controlled sirolimus with corticosteroids
Trial: 12742470
Drug: Sirolimus and
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus and steroids without calcineurin inhibitors
Trial: 9862578
Drug: Cathepsin D
RxNorm normalized name: Cathepsin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathepsin D positivity in oestrogen receptor-positive cases (57%)
Trial: 23103596
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 50 mg
Trial: 23103596
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 100 mg
Trial: 23103596
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch tablet)
Trial: 19944891
Drug: Azithromycin extended
RxNorm normalized name: azithromycin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin extended release (2-g single dose)
Trial: 19944891
Drug: Amoxicillin/clavulanate (875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (875 mg/125 mg every 12 hours for 10 days)
Trial: 21576440
Drug: Ertapenem 1
RxNorm normalized name: ertapenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem 1 g once daily
Trial: 2343722
Drug: droperidol 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.075 mg/kg
Trial: 2343722
Drug: dixyrazine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dixyrazine 0.25 mg/kg
Trial: 7429342
Drug: Cimetidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (20 mg/kg body weight/24 h)
Trial: 7429342
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (15 g/m2/24 h)
Trial: 7429342
Drug: Pancreatic supplement
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic supplement (Pancrelipase, 27 capsules per day)
Trial: 7429342
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cimetidine and sodium bicarbonate
Trial: 31594719
Drug: Microdose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose (100 μg) of atorvastatin
Trial: 31594719
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose (10 mg) of atorvastatin
Trial: 25583256
Drug: C1-esterase-inhibitor (C1-INH)
RxNorm normalized name: C1 esterase inhibitor
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-esterase-inhibitor (C1-INH) administered at 1,000 international units (IU) intravenously
Trial: 25583256
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and antihistamines (historical control)
Trial: 24164846
Drug: Sesame group
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame group (40 g/day sesame by oral administration for 2 months)
Trial: 7995010
Drug: 7-day nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day nicorandil (10 mg orally twice a day)
Trial: 7995010
Drug: 7-day intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day intermittent nitroglycerin patch (10 mg for 16 of 24 hours)
Trial: 2662829
Drug: Ketanserin 80
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 80 mg/day
Trial: 2662829
Drug: Pentoxiphylline 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxiphylline 1,200 mg/day
Trial: 29939049
Drug: Interim buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interim buprenorphine treatment (IBT; n = 25)
Trial: 26682747
Drug: GH(67) 67
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH(67) 67 μg/kg/day (once daily)
Trial: 26682747
Drug: GH(33) 33
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH(33) 33 μg/kg/day (once daily)
Trial: 26682747
Drug: GH(33x2) 33
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH(33x2) 33 μg/kg/day (divided into two daily injections)
Trial: 21575292
Drug: 2EHRZ/6HE regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2EHRZ/6HE regimen (daily EMB, INH, RMP, and PZA for 2 months, followed by EMB+INH for 6 months)
Trial: 21575292
Drug: 2(EHRZ)(3)/6HE regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2(EHRZ)(3)/6HE regimen (same drugs in the intensive phase but given three times weekly, followed by daily EMB+INH for 6 months)
Trial: 21575292
Drug: 2EHRZ/4HR regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2EHRZ/4HR regimen (same intensive phase as in regimen 1, followed by 4 months of daily RMP+INH)
Trial: 18291010
Drug: Traditional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional medicine as first-line treatment
Trial: 11022777
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD), 20 mg bid
Trial: 1611143
Drug: Cyclosporine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (10 mg/kg/day, single daily dose)
Trial: 31623621
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of firocoxib and PCSO-524
Trial: 26654115
Drug: CIT-S (Culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIT-S (Culturally Informed Therapy)
Trial: 22571902
Drug: Low-dose peginterferon-alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose peginterferon-alfa-2a (PEG-IFN)
Trial: 19799627
Drug: hydroxyurea and
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyurea and l-carnitine
Trial: 19799627
Drug: hydroxyurea, l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyurea, l-carnitine and magnesium chloride
Trial: 16261883
Drug: Defibrase 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrase 15 U plus normal saline 250 mL, followed by defibrase 5 U on days 3, 5, 7, and 9
Trial: 9617677
Drug: Allogenic bone
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogenic bone implants (ABI)
Trial: 28703950
Drug: Internet-based psychoeducation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based psychoeducation treatment group (n = 40)
Trial: 28430015
Drug: Mindfulness and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness and acceptance group therapy
Trial: 15138428
Drug: Misoprostol (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (active drug)
Trial: 10623692
Drug: Filgrastim or
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim or sequential regimen
Trial: 9369134
Drug: Etanidazole (Eta)
RxNorm normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etanidazole (Eta) with dose and schedule adjustment
Trial: 9369134
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy (RT) alone
Trial: 2412042
Drug: Beta‐adrenergic blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐adrenergic blockers alone
Trial: 18487480
Drug: Fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160 mg daily